Inflammatory Bowel Disease Treatment Market Growth and Trends (2024 – 2032)
The global market for inflammatory bowel disease (IBD) treatments is projected to expand from USD 19.91 billion in 2023 to approximately USD 33.19 billion by 2032. This growth is expected to occur at a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2024 to 2032.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5149
Report Highlights:
- Crohn’s disease accounted for the largest share of the market by disease type, with over 61% in 2023.
- TNF inhibitors held the biggest share among drug classes, representing 32% of the market in 2023.
- Retail pharmacies led the market, with a 36% market share in 2023.
- In Canada, someone is diagnosed with Crohn’s disease or ulcerative colitis every hour, making it one of the countries with the highest rates of these conditions globally.
About Inflammatory Bowel Disease (IBD):
Inflammatory bowel disease (IBD) refers to chronic inflammation in the digestive tract, and includes two main conditions: Crohn’s disease and ulcerative colitis. Ulcerative colitis causes inflammation and ulcers on the lining of the large intestine (colon) and rectum. Crohn’s disease, on the other hand, involves inflammation that can affect any part of the digestive tract, but primarily impacts the small intestine. In some cases, it can also involve the large intestine or even the upper gastrointestinal tract. Unlike ulcerative colitis, which only affects the mucosa of the large intestine and rectum, Crohn’s disease can affect deeper layers of the digestive tract and may also involve areas such as the mouth and anus.
Key Companies in the Inflammatory Bowel Disease Treatment Market
- AbbVie Inc.: A global biopharmaceutical company known for its innovative treatments, including those for inflammatory bowel disease (IBD). AbbVie’s portfolio includes medications that target key areas of IBD treatment.
- Takeda Pharmaceutical Company Limited: A leading global pharmaceutical company, Takeda is recognized for its commitment to developing therapies for complex conditions like Crohn’s disease and ulcerative colitis, offering various treatment options for IBD.
- Pfizer Inc.: Pfizer is a major player in the healthcare industry, with a wide range of medications for IBD. The company focuses on advancing science to help address the unmet needs of patients with chronic gastrointestinal diseases.
- Biogen: Known for its expertise in immunology and neurological treatments, Biogen also develops therapies for inflammatory bowel diseases, aiming to provide relief and long-term management solutions for patients with Crohn’s disease and ulcerative colitis.
- Novartis AG: A global healthcare leader, Novartis is involved in the development of treatments for various inflammatory diseases, including IBD. The company’s approach includes biologic therapies to manage symptoms and improve quality of life for patients.
- Eli Lilly and Company: Eli Lilly is dedicated to advancing IBD treatments through innovative therapies that target inflammation and improve patient outcomes, with a strong focus on immunotherapy.
- UCB S.A.: A biopharmaceutical company specializing in immunology, UCB develops therapies for chronic diseases like IBD, focusing on biologics and other advanced treatments for Crohn’s disease and ulcerative colitis.
- CELLTRION INC.: A leading global biopharmaceutical company, CELLTRION specializes in the development of biosimilars and innovative therapies, including treatments for inflammatory bowel diseases.
- Merck & Co., Inc.: Merck is a major player in the pharmaceutical industry, with a focus on IBD treatments. The company develops drugs that help manage both Crohn’s disease and ulcerative colitis, improving patient quality of life.
- Johnson & Johnson Services, Inc.: With a wide range of healthcare solutions, Johnson & Johnson is involved in the development of medications for managing inflammatory bowel diseases, particularly through its Janssen division, which offers biologic treatments for IBD.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/inflammatory-bowel-disease-treatment-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5149
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
